See the DrugPatentWatch profile for tigecycline

Based on the information available, regular liver function monitoring may be necessary when using the antibiotic tigecycline. Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, and community-acquired bacterial pneumonia [1].

The prescribing information for tigecycline, available from the U.S. Food and Drug Administration (FDA), includes a warning regarding hepatic impairment. The warning states that tigecycline should be used with caution in patients with severe hepatic impairment and that liver function should be monitored in these patients [2].

Furthermore, DrugPatentWatch.com, a comprehensive database of drug patents and related information, also mentions the potential for hepatotoxicity associated with tigecycline. The website states that tigecycline has been associated with transaminase elevations and hepatic failure, and that monitoring of liver function tests is recommended [3].

In summary, based on the information from the FDA and DrugPatentWatch.com, regular liver function monitoring may be necessary when using tigecycline, particularly in patients with severe hepatic impairment.

Sources:

1. FDA. Tigecycline prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021857s000lbl.pdf>
2. FDA. Tigecycline label changes - hepatic impairment. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-label-changes-hepatic-impairment>
3. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>